Friday, 16 October 2026European Markets

GUILLEMOT Stock Went Down By Over 31% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of GUILLEMOT (CAC 40: GUI.PA) fell by a staggering 31.43% in 21 sessions from $13.52 to $9.27 at 17:02 EST on Tuesday, following the last session's downward trend. CAC 40 is sliding 0.07% to $7,132.35, following the last session's downward trend.

About GUILLEMOT

Guillemot Corporation S.A. designs, manufactures, and sells interactive entertainment hardware and accessories in France, Germany, the United Kingdom, Spain, the United States, Canada, Italy, China, Belgium, and Romania. It offers digital hardware and peripherals under the Hercules brand name; PC and console gaming accessories under the Thrustmaster brand name; and DJ solutions for various connected devices under the DJUCED brand name. Guillemot Corporation S.A. was founded in 1984 and is based in Chantepie, France.

Earnings Per Share

As for profitability, GUILLEMOT has a trailing twelve months EPS of $1.95.

PE Ratio

GUILLEMOT has a trailing twelve months price to earnings ratio of 4.75. Meaning, the purchaser of the share is investing $4.75 for every dollar of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

GUILLEMOT's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for GUILLEMOT is 13565 which is 23.66% above its average volume of 10969.

More news about GUILLEMOT (GUI.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com